
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Hematol</journal-id><journal-id journal-id-type="iso-abbrev">Am. J. Hematol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1096-8652</journal-id><journal-id journal-id-type="publisher-id">AJH</journal-id><journal-title-group><journal-title>American Journal of Hematology</journal-title></journal-title-group><issn pub-type="ppub">0361-8609</issn><issn pub-type="epub">1096-8652</issn><publisher><publisher-name>John Wiley &#x00026; Sons, Inc.</publisher-name><publisher-loc>Hoboken, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32510647</article-id><article-id pub-id-type="pmc">7496181</article-id><article-id pub-id-type="doi">10.1002/ajh.25901</article-id><article-id pub-id-type="publisher-id">AJH25901</article-id><article-categories><subj-group subj-group-type="overline"><subject>Correspondence</subject></subj-group><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Limitations of the particle immunofiltration assay test for diagnosis of heparin&#x02010;induced thrombocytopenia</article-title><alt-title alt-title-type="left-running-head">CORRESPONDENCE</alt-title></title-group><contrib-group><contrib id="ajh25901-cr-0001" contrib-type="author" corresp="yes"><name><surname>Warkentin</surname><given-names>Theodore E.</given-names></name><xref ref-type="aff" rid="ajh25901-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ajh25901-aff-0002">
<sup>2</sup>
</xref><address><email>twarken@mcmaster.ca</email></address></contrib><contrib id="ajh25901-cr-0002" contrib-type="author"><name><surname>Cook</surname><given-names>Richard J.</given-names></name><xref ref-type="aff" rid="ajh25901-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="ajh25901-cr-0003" contrib-type="author"><name><surname>Greinacher</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="ajh25901-aff-0004">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="ajh25901-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Pathology and Molecular Medicine</named-content>
<institution>Michael G. DeGroote School of Medicine, McMaster University</institution>
<city>Hamilton</city>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="ajh25901-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Michael G. DeGroote School of Medicine, McMaster University</institution>
<city>Hamilton</city>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="ajh25901-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Statistics and Actuarial Science</named-content>
<institution>University of Waterloo</institution>
<city>Waterloo</city>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="ajh25901-aff-0004">
<label><sup>4</sup></label>
<institution>Institut f&#x000fc;r Immunologie und Transfusionsmedizin, Universit&#x000e4;tsmedizin Greifswald</institution>
<city>Greifswald</city>
<country country="DE">Germany</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Email: <email>twarken@mcmaster.ca</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>7</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2020</year></pub-date><volume>95</volume><issue>9</issue><issue-id pub-id-type="doi">10.1002/ajh.v95.9</issue-id><fpage>E250</fpage><lpage>E254</lpage><history><date date-type="received"><day>26</day><month>3</month><year>2020</year></date><date date-type="rev-recd"><day>31</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>02</day><month>6</month><year>2020</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 Wiley Periodicals LLC. <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2020 The Authors. <italic>American Journal of Hematology</italic> published by Wiley Periodicals LLC.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:AJH-95-E250.pdf"/><counts><fig-count count="1"/><table-count count="0"/><page-count count="5"/><word-count count="3023"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2020</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.0 mode:remove_FC converted:11.09.2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body id="ajh25901-body-0001"><p>
<named-content content-type="salutation">To the Editor:</named-content>
</p><sec sec-type="opening-section" id="ajh25901-sec-0001"><p>Heparin&#x02010;induced thrombocytopenia (HIT) is an immune&#x02010;mediated disorder caused by platelet&#x02010;activating antibodies that recognize complexes of (cationic) platelet factor 4 (PF4) bound to heparin or certain other polyanions.<xref rid="ajh25901-bib-0001" ref-type="ref">
<sup>1</sup>
</xref> Laboratory testing for the pathogenic &#x0201c;HIT antibodies&#x0201d; has focused on platelet activation assays (eg, serotonin&#x02010;release assay [SRA]<xref rid="ajh25901-bib-0002" ref-type="ref">
<sup>2</sup>
</xref>; heparin&#x02010;induced platelet activation assay [HIPA])<xref rid="ajh25901-bib-0003" ref-type="ref">
<sup>3</sup>
</xref> and PF4&#x02010;dependent enzyme&#x02010;immunoassays (EIAs).<xref rid="ajh25901-bib-0004" ref-type="ref">4</xref>, <xref rid="ajh25901-bib-0005" ref-type="ref">5</xref> However, assay results are not usually available on the same day of blood draw. Since HIT is ultimately diagnosed in only a minority of patients investigated per clinical suspicion,<xref rid="ajh25901-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> and given the need for timely treatment decisions, there is growing interest in rapid immunoassays for HIT.<xref rid="ajh25901-bib-0007" ref-type="ref">7</xref>, <xref rid="ajh25901-bib-0008" ref-type="ref">8</xref> The particle immunofiltration assay [PIFA (HealthTEST Heparin/Platelet Factor 4 Antibody Assay; Akers Biosciences, Inc., Thorofare, NJ]), a rapid immunoassay for detection of PF4/heparin antibodies, received clearance by the U.S. Food and Drug Administration (FDA) in 2004.<xref rid="ajh25901-bib-0009" ref-type="ref">9</xref>, <xref rid="ajh25901-bib-0010" ref-type="ref">10</xref>
</p><p>In 2016, Sun et al<xref rid="ajh25901-bib-0007" ref-type="ref">
<sup>7</sup>
</xref> included the PIFA in a systematic review of rapid immunoassays for HIT diagnosis based on one study,<xref rid="ajh25901-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> which found 100% PIFA sensitivity, albeit with a wide confidence interval (95% CI, 0.05&#x02010;1.00). The wide CI resulted from only two SRA&#x02010;positive study patients (as discussed later, these likely were false&#x02010;positive SRA results). In contrast, PIFA specificity was only 0.687 (95% CI, 0.586&#x02010;0.773). Further, these investigators<xref rid="ajh25901-bib-0007" ref-type="ref">
<sup>7</sup>
</xref> were not able to include in their review an earlier 2007 study we reported,<xref rid="ajh25901-bib-0010" ref-type="ref">
<sup>10</sup>
</xref> as our results were presented graphically (as ROC curve analyses) without providing the numerical data needed for inclusion in the systematic review. This likely also explains why our joint Hamilton/Greifswald PIFA evaluation (assessing 289 samples, including 25 HIT&#x02010;positive patients)<xref rid="ajh25901-bib-0010" ref-type="ref">
<sup>10</sup>
</xref> was not included in a later systematic review of rapid immunoassays by Nagler et al.<xref rid="ajh25901-bib-0008" ref-type="ref">
<sup>8</sup>
</xref>
</p><p>In the meantime, additional data on the PIFA has become available,<xref rid="ajh25901-bib-0012" ref-type="ref">12</xref>, <xref rid="ajh25901-bib-0013" ref-type="ref">13</xref>, <xref rid="ajh25901-bib-0014" ref-type="ref">14</xref>, <xref rid="ajh25901-bib-0015" ref-type="ref">15</xref> including two studies<xref rid="ajh25901-bib-0013" ref-type="ref">13</xref>, <xref rid="ajh25901-bib-0014" ref-type="ref">14</xref> presented in abstract form at the recent ASH annual meeting (December 2019). We now report the results of our analysis involving the sensitivity and specificity of the PIFA in all English language studies reported to date,<xref rid="ajh25901-bib-0010" ref-type="ref">10</xref>, <xref rid="ajh25901-bib-0011" ref-type="ref">11</xref>, <xref rid="ajh25901-bib-0012" ref-type="ref">12</xref>, <xref rid="ajh25901-bib-0013" ref-type="ref">13</xref>, <xref rid="ajh25901-bib-0014" ref-type="ref">14</xref>, <xref rid="ajh25901-bib-0015" ref-type="ref">15</xref> along with a recent study evaluating a modified PIFA, the PIFA PLUSS.<xref rid="ajh25901-bib-0016" ref-type="ref">
<sup>16</sup>
</xref> (The PIFA PLUSS includes a seraSTAT Rapid Blood Cell Separator, allowing for testing of whole blood, rather than serum.<xref rid="ajh25901-bib-0016" ref-type="ref">
<sup>16</sup>
</xref>) Prompted by a recent report,<xref rid="ajh25901-bib-0017" ref-type="ref">
<sup>17</sup>
</xref> we also obtained a report on the results of proficiency testing for the PIFA. Details regarding our systematic review and data synthesis are provided in a supplemental file which includes a PRISMA Flow Diagram (Figure <xref rid="ajh25901-supitem-0001" ref-type="supplementary-material">S1</xref> in <xref rid="ajh25901-supitem-0001" ref-type="supplementary-material">Appendix</xref> S1) and a QUADAS&#x02010;2 assessment of study quality (Table <xref rid="ajh25901-supitem-0001" ref-type="supplementary-material">S1</xref> in <xref rid="ajh25901-supitem-0001" ref-type="supplementary-material">Appendix</xref> S1).</p><p>We performed three analyses. First, we estimated PIFA sensitivity and specificity for those studies that determined HIT&#x02010;positive status by washed platelet activation test (SRA or HIPA) as the reference standard. If the study indicated that a particular sample was positive by SRA or HIPA but negative by PF4&#x02010;dependent EIA, the sample was regarded as HIT&#x02010;negative. This reduces risk of a false&#x02010;positive functional assay result,<xref rid="ajh25901-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> and also avoids potential bias towards too negative PIFA assessment because these sera might also not be recognized by other antigen tests. The 95% CIs for the individual studies were computed based on the method of Wilson,<xref rid="ajh25901-bib-0018" ref-type="ref">
<sup>18</sup>
</xref> as recommended by Agresti and Coull<xref rid="ajh25901-bib-0019" ref-type="ref">
<sup>19</sup>
</xref> for small samples. Overall estimates of PIFA sensitivity and specificity were obtained by jointly synthesizing the data from all seven studies using a bivariate random effects model for meta&#x02010;analysis of diagnostic test data, which accommodates study heterogeneity.<xref rid="ajh25901-bib-0020" ref-type="ref">
<sup>20</sup>
</xref>
</p><p>Second, for those studies that evaluated samples by both the PIFA and an EIA,<xref rid="ajh25901-bib-0010" ref-type="ref">10</xref>, <xref rid="ajh25901-bib-0011" ref-type="ref">11</xref>, <xref rid="ajh25901-bib-0013" ref-type="ref">13</xref>, <xref rid="ajh25901-bib-0016" ref-type="ref">16</xref> we constructed 2&#x02009;&#x000d7;&#x02009;2 tables by cross&#x02010;classifying samples according to the two methods. We then assessed the level of agreement between the two assays using Cohen&#x02019;s kappa statistic along with associated 95% CIs.<xref rid="ajh25901-bib-0021" ref-type="ref">
<sup>21</sup>
</xref> An overall measure of agreement was then computed by taking a weighted average of the study&#x02010;specific statistics using weights proportional to the inverse of the variances in order to maximize the precision of the resulting estimate.</p><p>Third, we obtained the results of a proficiency testing exercise for PIFA which was conducted from 2011 to 2019 by the External Quality Control for Assays and Tests (ECAT) Foundation. In this program, external laboratories tested two samples; one HIT&#x02010;positive, the other HIT&#x02010;negative. We determined yearly outcomes of participating laboratories obtaining the expected result of positive or negative for the two samples tested.</p><p>Figure <xref rid="ajh25901-fig-0001" ref-type="fig">1A</xref> shows the seven studies (in six reports<xref rid="ajh25901-bib-0010" ref-type="ref">10</xref>, <xref rid="ajh25901-bib-0011" ref-type="ref">11</xref>, <xref rid="ajh25901-bib-0012" ref-type="ref">12</xref>, <xref rid="ajh25901-bib-0013" ref-type="ref">13</xref>, <xref rid="ajh25901-bib-0014" ref-type="ref">14</xref>, <xref rid="ajh25901-bib-0015" ref-type="ref">15</xref>) which evaluated the PIFA against a platelet activation reference standard. Test sensitivity ranged from 0.600 to 0.875, except for one study reporting a 0% sensitivity based on 0/15 testing positive; test specificity ranged from 0.311 to 0.895. Combining all studies, the overall estimated sensitivity was 0.665 (95% CI, 0.533&#x02010;0.775) and the overall estimated specificity was 0.575 (95% CI, 0.353&#x02010;0.771).</p><fig fig-type="FIGURE" xml:lang="en" id="ajh25901-fig-0001" orientation="portrait" position="float"><label>FIGURE 1</label><caption><p>Three evaluations of the PIFA. A, Meta&#x02010;analysis of seven studies of the PIFA: platelet activation assay standard. All but one study used the serotonin&#x02010;release assay (SRA) as the reference standard; one study (Greifswald) used the heparin&#x02010;induced platelet activation (HIPA) test. Abbr.: HIT+, Heparin&#x02010;induced thrombocytopenia&#x02010;positive; HIT&#x02212;, HIT&#x02010;negative; PIFA+, Particle ImmunoFiltration Assay&#x02010;positive; PIFA&#x02212;, PIFA&#x02010;negative. The LR+ and LR&#x02212; calculations, based upon the overall meta&#x02010;analysis estimates of sensitivity and specificity (0.665 and 0.575, respectively), are as follows: (a) LR+ = sensitivity/[1&#x02010;specificity] = 0.665/[1&#x02010;0.575] = 1.56. (b) LR&#x02212; = [1&#x02010;sensitivity]/specificity = [1&#x02010;0.665]/0.575 = 0.583. B, Agreement analysis of five studies of the PIFA or PIFA PLUSS: EIA standard. Abbr.: +, positive; &#x02212;, negative; EIA&#x02010;G, IgG&#x02010;specific enzyme&#x02010;immunoassay; EIA&#x02010;GAM, polyspecific enzyme&#x02010;immunoassay that detects antibodies of IgG, IgA, and/or IgM classes. C, Results of external quality assessment of the PIFA from the ECAT Foundation. No data were available for 2013, 2014, or 2015. During each of the six years shown, each participating laboratory received one HIT&#x02010;positive and one HIT&#x02010;negative sample. <sup>a</sup> For performing the meta&#x02010;analysis, a continuity correction of 0.5 was added to all cells for the Miami and Gainesville studies (because one or more cells for these studies had a value of 0). <sup>b</sup>HIT&#x02010;positive samples were prepared by diluting a strong&#x02010;positive HIT sample with normal pooled plasma. <sup>c</sup>HIT&#x02010;negative samples were normal pooled plasma. <sup>d</sup>One borderline positive sample was classified as &#x0201c;positive&#x0201d; for purposes of analysis</p></caption><graphic id="nlm-graphic-1" xlink:href="AJH-95-E250-g001"/></fig><p>In our evaluation of the Miami study,<xref rid="ajh25901-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> both SRA&#x02010;positive patients were classified as HIT&#x02010;negative based upon negative EIA results (these patients also had low 4Ts scores and were not regarded by the study authors as having had HIT).<xref rid="ajh25901-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> We therefore also assessed overall PIFA sensitivity and specificity omitting the Miami study (as there were no HIT&#x02010;positive subjects to judge test sensitivity). We performed another analysis omitting the Brooklyn study (which was reported in abstract form in 2014 and did not give a comparison with an EIA).<xref rid="ajh25901-bib-0012" ref-type="ref">
<sup>12</sup>
</xref> We also performed an additional analysis omitting the Gainesville study (as this study appeared to be an outlier).<xref rid="ajh25901-bib-0015" ref-type="ref">
<sup>15</sup>
</xref> All estimated sensitivities were below 0.714, corresponding to values too low for an acceptable screening test; further, no analysis showed an estimated specificity greater than 0.575.</p><p>Figure <xref rid="ajh25901-fig-0001" ref-type="fig">1B</xref> shows those studies<xref rid="ajh25901-bib-0010" ref-type="ref">10</xref>, <xref rid="ajh25901-bib-0011" ref-type="ref">11</xref>, <xref rid="ajh25901-bib-0013" ref-type="ref">13</xref>, <xref rid="ajh25901-bib-0016" ref-type="ref">16</xref> that permit comparison of PIFA reactivity vs an EIA. None of the five studies yielded CIs demonstrating improvement over chance agreement. Moreover, when pooling the kappa statistic across studies, the overall measure did not suggest agreement beyond chance. Indeed, the overall raw agreement (pooled data) showed only 51.5% agreement. These results contrast with data presented on two FDA websites,<xref rid="ajh25901-bib-0022" ref-type="ref">22</xref>, <xref rid="ajh25901-bib-0023" ref-type="ref">23</xref> suggesting assay performance may have changed.</p><p>Figure <xref rid="ajh25901-fig-0001" ref-type="fig">1C</xref> shows the results of the ECAT Foundation external quality assessment. The external laboratories generally obtained a positive PIFA result for the six HIT&#x02010;positive samples evaluated (28/30 [93.3%]); however, the laboratories also tended to obtain a positive PIFA result for the corresponding 6 HIT&#x02010;<italic>negative</italic> samples, that is, the expected negative results were seen in only 7/29 (24.1%) of the HIT&#x02010;negative samples.</p><p>We note that poor assay performance can cause problems in patient management, as illustrated by a report<xref rid="ajh25901-bib-0024" ref-type="ref">
<sup>24</sup>
</xref> of a patient with a clinical picture of HIT (thrombocytopenia; necrotizing skin lesions at heparin injection sites; deep&#x02010;vein thrombosis; post&#x02010;heparin bolus anaphylactoid reaction) and strong&#x02010;positive testing by EIA and SRA; however, the PIFA test was repeatedly negative.</p><p>One way of assessing assay utility is through evaluation of its impact on clinical decision making. For example, the likelihood ratio of a positive test result (LR+) and the likelihood ratio of a negative test result (LR&#x02212;) reflect how the odds of disease are altered with a positive and negative test result, respectively. For the PIFA, the overall LR+ (sensitivity/[1&#x02010;specificity]) and LR&#x02212; ([1&#x02010;sensitivity]/specificity) are 1.56 and 0.582, respectively (see Figure legend for detailed calculations); thus, for a patient judged clinically to have a 50% probability of HIT, the pre&#x02010;test odds are 1 (0.50/0.50), and the resulting post&#x02010;test probabilities are approximately 0.60 and 0.37 for a positive and negative PIFA test result, respectively; these values are not so different from the initial starting estimate (0.50). In contrast, the LR+ and LR&#x02212; values for the EIA (~6 and&#x02009;~0.01, respectively)<xref rid="ajh25901-bib-0025" ref-type="ref">
<sup>25</sup>
</xref> would result in post&#x02010;test probabilities of 0.86 and &#x0003c;0.01, and for two other rapid assays<xref rid="ajh25901-bib-0025" ref-type="ref">25</xref>, <xref rid="ajh25901-bib-0026" ref-type="ref">26</xref> the corresponding LR+ values (~16 and ~66, respectively) and LR&#x02212; values (approximately 0.034 and 0.031, respectively) would result in post&#x02010;test probabilities of 0.94&#x02010;0.98 and 0.03, respectively. Moreover, whereas the PIFA only provides a binary outcome (positive/negative), the EIA and other rapid immunoassays provide semiquantitative results, allowing for even greater estimates of LR+ for strong&#x02010;positive results.<xref rid="ajh25901-bib-0025" ref-type="ref">25</xref>, <xref rid="ajh25901-bib-0026" ref-type="ref">26</xref>
</p><p>The poor performance of the PIFA is clear from Figure <xref rid="ajh25901-fig-0001" ref-type="fig">1A,B</xref>. Notably, there is significant heterogeneity between the studies with homogeneity tests yielding <italic>P</italic>&#x02009;&#x0003c;&#x02009;.001 for both sensitivity and specificity. Also notable, however, is the strong consistency in the results among the participating laboratories from the ECAT Foundation program, with results consistently incorrect for most of the HIT&#x02010;negative samples.</p><p>In summary, our analysis of available data indicates that the PIFA provides minimal if any value for HIT diagnosis. Further, PIFA results do not correlate with EIA reactivity. Overall, the data are compatible with a test that yields a positive result approximately 42% of the time (all PIFA studies pooled<xref rid="ajh25901-bib-0010" ref-type="ref">10</xref>, <xref rid="ajh25901-bib-0011" ref-type="ref">11</xref>, <xref rid="ajh25901-bib-0012" ref-type="ref">12</xref>, <xref rid="ajh25901-bib-0013" ref-type="ref">13</xref>, <xref rid="ajh25901-bib-0014" ref-type="ref">14</xref>, <xref rid="ajh25901-bib-0015" ref-type="ref">15</xref>), with minimal if any association with whether the patient has HIT or not (Figure <xref rid="ajh25901-fig-0001" ref-type="fig">1A</xref>), or indeed whether anti&#x02010;PF4/heparin antibodies detectable by EIA are present or not (Figure <xref rid="ajh25901-fig-0001" ref-type="fig">1B</xref>). As indicated by the single PIFA PLUSS study,<xref rid="ajh25901-bib-0016" ref-type="ref">
<sup>16</sup>
</xref> the new test version has similar suboptimal performance. The ECAT Foundation proficiency testing evaluation also raises concerns on the ability of the PIFA to distinguish between positive and negative HIT samples. Pending future supportive data, the PIFA test bears substantial risk for HIT overdiagnosis and, in our opinion, also for false&#x02010;negative results pointing away from a true diagnosis of HIT.</p></sec><sec sec-type="COI-statement" id="ajh25901-sec-0004"><title>CONFLICT OF INTEREST</title><p>T.E.W. has received lecture honoraria from Alexion and Instrumentation Laboratory and royalties from Informa (Taylor &#x00026; Francis); has provided consulting services to Aspen Global, Bayer, CSL Behring, Ergomed, Instrumentation Laboratory, and Octapharma; has received research funding from Instrumentation Laboratory; and has provided expert witness testimony relating to heparin induced thrombocytopenia (HIT) and non HIT thrombocytopenic and coagulopathic disorders, including on utility of laboratory assays for HIT. A.G. has received lecture honoraria from Instrumentation Laboratory and royalties from Informa (Taylor &#x00026; Francis); has provided consulting services to Aspen Global, Aspen Germany, Ergomed, and Chromatec; and has received research funding from BioKit. R.J.C. discloses no relevant conflicts of interest.</p><p>ORCID profiles: T.E.W. 0000&#x02010;0002&#x02010;8046&#x02010;7588; A.G. 0000&#x02010;0001&#x02010;8343&#x02010;7336.</p></sec><sec id="ajh25901-sec-0003"><title>AUTHOR CONTRIBUTIONS</title><p>T.E.W. designed the study, reviewed the Hamilton data, analyzed the publically available PIFA data, and wrote the first draft of the manuscript. A.G. reviewed the Greifswald data and helped edit the manuscript. R.J.C. provided statistical expertise and analyses. All three authors approved the final version of the paper.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="ajh25901-supitem-0001"><caption><p>
<bold>Appendix</bold>
<bold>S1.</bold> Supporting Information.</p></caption><media xlink:href="AJH-95-E250-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="ajh25901-sec-0002"><title>ACKNOWLEDGMENT</title><p>The authors thank Dr. Daniel H. Kett, MD (University of Miami) for providing additional data regarding one of the studies.<xref rid="ajh25901-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> We also thank Jo&#x02010;Ann I. Sheppard for preparing Figure <xref rid="ajh25901-fig-0001" ref-type="fig">1</xref> and Figure <xref rid="ajh25901-supitem-0001" ref-type="supplementary-material">S1</xref>, and Ker&#x02010;Ai Lee for assistance with statistical calculations.</p></ack><ref-list id="ajh25901-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="ajh25901-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ajh25901-cit-0001">
<string-name>
<surname>Pishko</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Cuker</surname>
<given-names>A</given-names>
</string-name>. <article-title>Heparin&#x02010;induced thrombocytopenia in cardiac surgery patients</article-title>. <source xml:lang="en">Semin Thromb Hemost</source>. <year>2017</year>;<volume>43</volume>(<issue>7</issue>):<fpage>691</fpage>&#x02010;<lpage>698</lpage>.<pub-id pub-id-type="pmid">28597462</pub-id></mixed-citation></ref><ref id="ajh25901-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ajh25901-cit-0002">
<string-name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Nazy</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Sheppard</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Kelton</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Arnold</surname>
<given-names>DM</given-names>
</string-name>. <article-title>Serotonin&#x02010;release assay&#x02010;negative heparin&#x02010;induced thrombocytopenia</article-title>. <source xml:lang="en">Am J Hematol</source>. <year>2020</year>;<volume>95</volume>(<issue>1</issue>):<fpage>38</fpage>&#x02010;<lpage>47</lpage>.<pub-id pub-id-type="pmid">31621093</pub-id></mixed-citation></ref><ref id="ajh25901-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ajh25901-cit-0003">
<string-name>
<surname>Greinacher</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Michels</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kiefel</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Mueller&#x02010;Eckhardt</surname>
<given-names>C</given-names>
</string-name>. <article-title>A rapid and sensitive test for diagnosing heparin&#x02010;induced thrombocytopenia</article-title>. <source xml:lang="en">Thromb Haemost</source>. <year>1991</year>;<volume>66</volume>(<issue>6</issue>):<fpage>734</fpage>&#x02010;<lpage>736</lpage>.<pub-id pub-id-type="pmid">1796420</pub-id></mixed-citation></ref><ref id="ajh25901-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ajh25901-cit-0004">
<string-name>
<surname>Visentin</surname>
<given-names>GP</given-names>
</string-name>, <string-name>
<surname>Moghaddam</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Beery</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>McFarland</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Aster</surname>
<given-names>RH</given-names>
</string-name>. <article-title>Heparin is not required for detection of antibodies associated with heparin&#x02010;induced thrombocytopenia</article-title>. <source xml:lang="en">J Lab Clin Med</source>. <year>2001</year>;<volume>138</volume>(<issue>1</issue>):<fpage>22</fpage>&#x02010;<lpage>31</lpage>.<pub-id pub-id-type="pmid">11433225</pub-id></mixed-citation></ref><ref id="ajh25901-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ajh25901-cit-0005">
<string-name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Sheppard</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Kelton</surname>
<given-names>JG</given-names>
</string-name>. <article-title>The use of well&#x02010;characterized sera for the assessment of new diagnostic enzyme&#x02010;immunoassays for the diagnosis of heparin&#x02010;induced thrombocytopenia</article-title>. <source xml:lang="en">J Thromb Haemost</source>. <year>2010</year>;<volume>8</volume>(<issue>1</issue>):<fpage>216</fpage>&#x02010;<lpage>218</lpage>.<pub-id pub-id-type="pmid">19818000</pub-id></mixed-citation></ref><ref id="ajh25901-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ajh25901-cit-0006">
<string-name>
<surname>Greinacher</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Juhl</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Strobel</surname>
<given-names>U</given-names>
</string-name>, et al. <article-title>Heparin&#x02010;induced thrombocytopenia: a prospective study on the incidence, platelet&#x02010;activating capacity and clinical significance of anti&#x02010;PF4/heparin antibodies of the IgG, IgM, and IgA classes</article-title>. <source xml:lang="en">J Thromb Haemost</source>. <year>2007</year>;<volume>5</volume>(<issue>8</issue>):<fpage>1666</fpage>&#x02010;<lpage>1673</lpage>.<pub-id pub-id-type="pmid">17488345</pub-id></mixed-citation></ref><ref id="ajh25901-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ajh25901-cit-0007">
<string-name>
<surname>Sun</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gimotty</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Lakshmanan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cuker</surname>
<given-names>A</given-names>
</string-name>. <article-title>Diagnostic accuracy of rapid immunoassays for heparin&#x02010;induced thrombocytopenia. A systematic review and meta&#x02010;analysis</article-title>. <source xml:lang="en">Thromb Haemost</source>. <year>2016</year>;<volume>115</volume>(<issue>5</issue>):<fpage>1044</fpage>&#x02010;<lpage>1055</lpage>.<pub-id pub-id-type="pmid">26763074</pub-id></mixed-citation></ref><ref id="ajh25901-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ajh25901-cit-0008">
<string-name>
<surname>Nagler</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bachmann</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>ten Cate</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>ten Cate&#x02010;Hoek</surname>
<given-names>A</given-names>
</string-name>. <article-title>Diagnostic value of immunoassays for heparin&#x02010;induced thrombocytopenia: a systematic review and meta&#x02010;analysis</article-title>. <source xml:lang="en">Blood</source>. <year>2016</year>;<volume>127</volume>(<issue>5</issue>):<fpage>546</fpage>&#x02010;<lpage>557</lpage>.<pub-id pub-id-type="pmid">26518436</pub-id></mixed-citation></ref><ref id="ajh25901-bib-0009"><label>9</label><mixed-citation publication-type="book" id="ajh25901-cit-0009">
<string-name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Greinacher</surname>
<given-names>A</given-names>
</string-name>. <chapter-title>Laboratory testing for heparin&#x02010;induced thrombocytopenia</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Warkentin</surname><given-names>TE</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Greinacher</surname><given-names>A</given-names></name></person-group>, eds. <source xml:lang="en">Heparin&#x02010;Induced Thrombocytopenia</source>. <edition designator="5">5th ed.</edition>
<publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>CRC Press</publisher-name>; <year>2013</year>:<fpage>272</fpage>&#x02010;<lpage>314</lpage>.</mixed-citation></ref><ref id="ajh25901-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ajh25901-cit-0010">
<string-name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Sheppard</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Raschke</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Greinacher</surname>
<given-names>A</given-names>
</string-name>. <article-title>Performance characteristics of a rapid assay for anti&#x02010;PF4/heparin antibodies, the Particle ImmunoFiltration Assay</article-title>. <source xml:lang="en">J Thromb Haemost</source>. <year>2007</year>;<volume>5</volume>(<issue>11</issue>):<fpage>2308</fpage>&#x02010;<lpage>2310</lpage>.<pub-id pub-id-type="pmid">17697138</pub-id></mixed-citation></ref><ref id="ajh25901-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ajh25901-cit-0011">
<string-name>
<surname>Andrews</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Cubillos</surname>
<given-names>GF</given-names>
</string-name>, <string-name>
<surname>Paulino</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Seckinger</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Kett</surname>
<given-names>DH</given-names>
</string-name>. <article-title>Prospective observational evaluation of the particle immunofiltration anti&#x02010;platelet factor 4 rapid assay in MICU patients with thrombocytopenia</article-title>. <source xml:lang="en">Crit Care</source>. <year>2013</year>;<volume>17</volume>(<issue>4</issue>):<fpage>R143</fpage>.<pub-id pub-id-type="pmid">23876263</pub-id></mixed-citation></ref><ref id="ajh25901-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="ajh25901-cit-0012">
<string-name>
<surname>Nannapaneni</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Malhotra</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Simon</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>A rapid heparin antibody detection assay performs better than 4T&#x02019;s score in predicting HIT diagnosis: a single community medical center retrospective analysis</article-title>. [Abstract]. <source xml:lang="en">Blood</source>. <year>2014</year>;<volume>124</volume>(<issue>21</issue>):<fpage>1457</fpage>.</mixed-citation></ref><ref id="ajh25901-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="ajh25901-cit-0013">
<string-name>
<surname>Kra</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Horng</surname>
<given-names>H</given-names>
</string-name>. <article-title>Utility and pitfalls of stepwise laboratory testing for heparin induced thrombocytopenia: retrospective review from an academic medical center</article-title>. [Abstract]. <source xml:lang="en">Blood</source>. <year>2019</year>;<volume>132</volume>(<issue>Suppl. 1</issue>):<fpage>2371</fpage>.</mixed-citation></ref><ref id="ajh25901-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="ajh25901-cit-0014">
<string-name>
<surname>Ball</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Adhikari</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Sultan</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Effective implementation of a structured protocol for facilitation of the judicious use of antibody test for diagnosis of heparin induced thrombocytopenia</article-title>. [Abstract]. <source xml:lang="en">Blood</source>. <year>2019</year>;<volume>134</volume>(<issue>Suppl 1</issue>):<fpage>3462</fpage>.</mixed-citation></ref><ref id="ajh25901-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="ajh25901-cit-0015">
<string-name>
<surname>De Luna</surname>
<given-names>MHIT</given-names>
</string-name>. <article-title>Anti&#x02010;platelet factor 4&#x02010;heparin (pf4&#x02010;h) assay validation and comparison study</article-title>. [Abstract]. <source xml:lang="en">Am J Clin Path</source>. <year>2019</year>;<volume>152</volume>(<issue>Suppl. 1</issue>):<fpage>S124</fpage>.</mixed-citation></ref><ref id="ajh25901-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="ajh25901-cit-0016">
<string-name>
<surname>Compton</surname>
<given-names>FB</given-names>
</string-name>, <string-name>
<surname>Alrabeh</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>
<given-names>LQ</given-names>
</string-name>, <string-name>
<surname>Nedelcu</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Wahed</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>
<given-names>ND</given-names>
</string-name>. <article-title>PIFA PLUSS P4 assay for screening of heparin&#x02010;induced thrombocytopenia</article-title>. <source xml:lang="en">Lab Med</source>. <year>2019</year>;<volume>50</volume>(<issue>1</issue>):<fpage>73</fpage>&#x02010;<lpage>77</lpage>.<pub-id pub-id-type="pmid">30085261</pub-id></mixed-citation></ref><ref id="ajh25901-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="ajh25901-cit-0017">
<string-name>
<surname>Liederman</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>van Cott</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Smock</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Meijer</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Selby</surname>
<given-names>R</given-names>
</string-name>. <article-title>Heparin&#x02010;induced thrombocytopenia: an international assessment of the quality of laboratory testing</article-title>. <source xml:lang="en">J Thromb Haemost</source>. <year>2020</year>;<volume>17</volume>(<issue>12</issue>):<fpage>2123</fpage>&#x02010;<lpage>2130</lpage>.</mixed-citation></ref><ref id="ajh25901-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="ajh25901-cit-0018">
<string-name>
<surname>Wilson</surname>
<given-names>EB</given-names>
</string-name>. <article-title>Probable inference, the law of succession, and statistical inference</article-title>. <source xml:lang="en">J Am Stat Assoc</source>. <year>1927</year>;<volume>22</volume>(<issue>158</issue>):<fpage>209</fpage>&#x02010;<lpage>212</lpage>.</mixed-citation></ref><ref id="ajh25901-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="ajh25901-cit-0019">
<string-name>
<surname>Agresti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Coull</surname>
<given-names>BA</given-names>
</string-name>. <article-title>Approximate is better than &#x0201c;exact&#x0201d; for interval estimation of binomial proportions</article-title>. <source xml:lang="en">Am Stat</source>. <year>1998</year>;<volume>52</volume>(<issue>2</issue>):<fpage>119</fpage>&#x02010;<lpage>126</lpage>.</mixed-citation></ref><ref id="ajh25901-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="ajh25901-cit-0020">
<string-name>
<surname>Reitsma</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Glas</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rutjes</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Scholten</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bossuyt</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Zwinderman</surname>
<given-names>A</given-names>
</string-name>. <article-title>Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews</article-title>. <source xml:lang="en">J Clin Epidemiol</source>. <year>2005</year>;<volume>58</volume>(<issue>10</issue>):<fpage>982</fpage>&#x02010;<lpage>990</lpage>.<pub-id pub-id-type="pmid">16168343</pub-id></mixed-citation></ref><ref id="ajh25901-bib-0021"><label>21</label><mixed-citation publication-type="book" id="ajh25901-cit-0021">
<string-name>
<surname>Fleiss</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Levin</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Paik</surname>
<given-names>MC</given-names>
</string-name>. <source xml:lang="en">Statistical Methods for Rates and Proportions</source>. <publisher-loc>Hoboken, NJ</publisher-loc>: <publisher-name>John Wiley &#x00026; Sons</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="ajh25901-bib-0022"><label>22</label><mixed-citation publication-type="miscellaneous" id="ajh25901-cit-0022">
<article-title>510(k) Substantial equivalence determination K040293</article-title> (28 May 2004). <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/cdrh_docs/pdf4/K040293.pdf">www.accessdata.fda.gov/cdrh_docs/pdf4/K040293.pdf</ext-link>. Accessed February 11, 2020.</mixed-citation></ref><ref id="ajh25901-bib-0023"><label>23</label><mixed-citation publication-type="miscellaneous" id="ajh25901-cit-0023">
<article-title>510(k) Substantial equivalence determination K052697</article-title> (4 Jan 2006) <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/cdrh_docs/pdf5/K052697.pdf">www.accessdata.fda.gov/cdrh_docs/pdf5/K052697.pdf</ext-link>. Accessed February 11, 2020.</mixed-citation></ref><ref id="ajh25901-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="ajh25901-cit-0024">
<string-name>
<surname>Tassava</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</string-name>. <article-title>Non&#x02010;injection site necrotic skin lesions complicating postoperative heparin thromboprophylaxis</article-title>. <source xml:lang="en">Am J Hematol</source>. <year>2015</year>;<volume>90</volume>(<issue>8</issue>):<fpage>747</fpage>&#x02010;<lpage>750</lpage>.<pub-id pub-id-type="pmid">25808584</pub-id></mixed-citation></ref><ref id="ajh25901-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="ajh25901-cit-0025">
<string-name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Sheppard</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Linkins</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Arnold</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Nazy</surname>
<given-names>I</given-names>
</string-name>. <article-title>Performance characteristics of an automated latex immunoturbidimetric assay [HemosIL HIT&#x02010;Ab<sub>(PF4&#x02010;H)</sub>] for the diagnosis of immune heparin&#x02010;induced thrombocytopenia</article-title>. <source xml:lang="en">Thromb Res</source>. <year>2017</year>;<volume>153</volume>:<fpage>108</fpage>&#x02010;<lpage>117</lpage>.<pub-id pub-id-type="pmid">28391124</pub-id></mixed-citation></ref><ref id="ajh25901-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="ajh25901-cit-0026">
<string-name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Sheppard</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Linkins</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Arnold</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Nazy</surname>
<given-names>I</given-names>
</string-name>. <article-title>High sensitivity and specificity of an automated IgG&#x02010;specific chemiluminescence immunoassay for diagnosis of HIT</article-title>. <source xml:lang="en">Blood</source>. <year>2018</year>;<volume>132</volume>(<issue>12</issue>):<fpage>1345</fpage>&#x02010;<lpage>1349</lpage>.<pub-id pub-id-type="pmid">30064975</pub-id></mixed-citation></ref></ref-list></back></article>